Objective:
To calculate direct retail pharmacotherapy and monitoring costs for type 2 diabetes mellitus (T2DM) and obesity in adults in the Russian Federation based on the current Ministry of Health clinical guidelines.
Material and methods.
Using median retail prices from the apteka.ru and uteka.ru pharmacy aggregators in April 2026, costs for 14 T2DM and 5 obesity pharmacotherapy regimens were calculated. The dataset included 254 price items for T2DM drugs and 44 items for obesity drugs. The analysis was conducted from the patient out-of-pocket perspective. Direct non-drug medical monitoring costs, including laboratory tests, physician visits, and self-monitoring of blood glucose, were additionally assessed.
Results.
T2DM pharmacotherapy costs ranged from 175 to 14,716 rubles per month, corresponding to an approximately 84-fold difference between the least and most expensive regimens. Three cost strata were identified: (I) low-cost (12,000 rubles per month) strata. Low-cost regimens included metformin and its combinations with sulfonylureas; medium-cost regimens included dipeptidyl peptidase-4 inhibitors, sodium-glucose transport-2 inhibitors, insulin and injectable semaglutide; high-cost regimens included liraglutide, tirzepatide, and oral semaglutide. Obesity pharmacotherapy costs ranged from 2,958 rubles per month for sibutramine to 29,568 rubles per month for semaglutide (2.4 mg once a week). The total annual recommended monitoring costs including self-monitoring of blood glucose reached 32,900– 63,200 rubles for patients receiving oral therapy and 51,150–99,700 rubles for patients receiving insulin studies.
Conclusion.
Transition to modern pharmacotherapy regimens for T2DM and obesity is associated with a substantial increase in direct drug expenditure. Injectable semaglutide belongs to the medium-cost stratum, whereas oral semaglutide remains in the high-cost stratum, which may reflect the technological complexity of the oral salcaprozate sodium formulation and limited competition in this segment. Accounting for monitoring costs shows that the true direct financial burden on patients substantially exceeds drug costs, particularly in the low- and medium-cost strata. These data provide a basis for subsequent pharmacoeconomic analyses.